A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Dalotuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Jun 2017 Biomarkers information updated
- 05 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 05 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.